BioLineRx (NASDAQ:BLRX) & CRISPR Therapeutics (NASDAQ:CRSP) Critical Review
by Mitch Edgeman · The Markets DailyCRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and BioLineRx (NASDAQ:BLRX – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.
Volatility and Risk
CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for CRISPR Therapeutics and BioLineRx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CRISPR Therapeutics | 1 | 6 | 9 | 2 | 2.67 |
| BioLineRx | 1 | 0 | 0 | 0 | 1.00 |
CRISPR Therapeutics currently has a consensus price target of $67.94, suggesting a potential upside of 22.55%. Given CRISPR Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe CRISPR Therapeutics is more favorable than BioLineRx.
Earnings & Valuation
This table compares CRISPR Therapeutics and BioLineRx”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics | $3.51 million | 1,527.21 | -$581.60 million | ($4.76) | -11.65 |
| BioLineRx | $1.18 million | 9.66 | -$1.17 million | ($1.69) | -1.39 |
BioLineRx has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares CRISPR Therapeutics and BioLineRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics | -3,368.72% | -24.39% | -18.25% |
| BioLineRx | -502.08% | -34.80% | -18.27% |
Summary
CRISPR Therapeutics beats BioLineRx on 11 of the 15 factors compared between the two stocks.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.